While the '3G' study did not establish clinical utility, the researchers said it shows genomic profiling to guide gastric cancer treatment is feasible.
Five Prime will use an IHC CDx to analyze the use of investigational drug candidates in patients with advanced gastric or gastroesophageal junction cancer.
The ctDNA assay will be used to select patients for Phase 3 of Five Prime's registrational trial investigating bemarituzumab in gastric cancer patients.
Researchers associated with the Cancer Genome Atlas (TCGA) Research Network will publish more than 25 papers this week to discuss findings from the initiative.
A proteomic and targeted exome sequencing study of diffuse-type gastric cancer led to proteomic subtypes with distinct mutation, survival, and potential treatment patterns.
Examining five types of bacterial environments in patients' stomachs, researchers found that non-Helicobacter pylori microbiota may lead to gastric cancer development.
